Nasdaq-listed biotech firm Sonnet BioTherapeutics announced Monday a $888 million merger agreement with Rorschach I LLC, an ...

Sonnet BioTherapeutics merges to launch Hyperliquid Strategies, holding $888M in HYPE tokens and cash to build a leading ...

Sonnet BioTherapeutics enters into an agreement to transform into the largest U.S.-based publicly listed company to hold HYPE ...

Sonnet BioTherapeutics (NASDAQ:SONN) saw its stock soar by 290% after announcing an $888 million business combination that will pivot the company into a cryptocurrency treasury focused on HYPE tokens.

Hyperliquid (HYPE) trades near $48 on Monday following Sonnet BioTherapeutics' (SONN) announcement that it has entered a ...

HYPE rallies toward $50 after Sonnet BioTherapeutics combines with Rorschach to launch a $583 million Hyperliquid token ...

Sonnet to merge with crypto-backed firm, forming Hyperliquid Strategies with $888 million in assets, plus HYPE blockchain ...

Sonnet BioTherapeutics will transform into a new entity called HyperLiquid Strategies at the agreement's close. The new company is expected to hold 12.6 million HYPE tokens and gross cash invested of ...

Sonnet BioTherapeutics pivots to crypto with $888M deal, forming Hyperliquid Strategies Inc. to hold 12.6M HYPE tokens.

Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) fell 5.54% on Thursday to close at $3.92, before rebounding 14.29% in after-hours trading to $4.48, amid concerns of a potential NASDAQ delisting.

Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON‑080 was reviewed by the study's Data Safety Monitoring Board (DSMB) The adverse event profile and ...